Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Israeli cannabis firm Kanabo to be bought by London's Spinnaker

Published 02/12/2019, 12:52
Updated 02/12/2019, 12:57
© Reuters.  Israeli cannabis firm Kanabo to be bought by London's Spinnaker

© Reuters. Israeli cannabis firm Kanabo to be bought by London's Spinnaker

(Reuters) - Israel's Kanabo Research has agreed to be bought by cash shell Spinnaker Opportunities (L:SOP), in what could lead to the first listing of a cannabis company on London's main stock market.

In a statement on Monday, Spinnaker did not disclose the value of the proposed reverse takeover, which would allow Tel Aviv-based Kanabo to bypass traditional listing rules.

The companies did not immediately respond to requests for comment on the value.

Spinnaker has also agreed to pump in 200,000 pounds ($256,600.00) into Kanabo, which is looking to grow sales. The Israeli company already has a promise of 1.4 million pounds from the London-listed firm.

Kanabo supplies medical cannabis products that do not contain THC, the psychoactive ingredient in marijuana which causes hallucinations. Its products are delivered through a vaping device.

The London Stock Exchange has not seen many pot firms in its indexes. GW Pharmaceuticals (O:GWPH), which makes marijuana-based epilepsy treatments, was listed on the bourse's junior market between 2001 and 2016.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.